Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A randomised, double-blind phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a (roferon) versus interferon alfa-2a and placebo as first line treatment administered to nephrectomized patients with metastatic clear cell renal cell carcinoma
bevacizumab
BO17705 (AVOREN)
NCT00738530
renal cell carcinoma
Phase 3
 
January 2014

Powered by ideaPoint, Inc.